Aclaris Therapeutics Inc logo

Aclaris Therapeutics Inc(ACRS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
4-STAR RATING
PASS
LAST CLOSE
$3.44
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ACRS

11/20/2026: ACRS (4-star) is currently NOT-A-BUY. Pass it for now.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for immuno-inflammatory and dermatological conditions. The company's primary strength lies in its promising biologic pipeline, including assets like bosakitug and ATI-052, supported by an experienced leadership team. Its core investment narrative centers on anticipated clinical trial readouts that could validate its targeted approach and attract partnership interest. However, the company faces substantial execution risks, ongoing net losses, and fierce competition from well-funded biotechnology peers. Aclaris best suits growth-oriented or risk-tolerant investors willing to monitor clinical milestones, regulatory updates, and cash runway management.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers long-term clinical growth potential if its novel immunology pipeline succeeds, but lacks predictable commercial revenue today.
Momentum investorStrong fit while signal remains positiveMomentum is highly sensitive to upcoming clinical data readouts and positive regulatory or trial catalysts.
Value investorWeak fitTraditional value metrics do not apply given ongoing net losses and pre-commercial pipeline valuation.
Dividend investorWeak fitThe company does not pay dividends and retains all cash to fund clinical research.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high price volatility and binary clinical trial risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock prices react sharply to clinical trial updates, regulatory milestones, and broader biotech sentiment.
Valuation riskMedium / highValuation depends heavily on subjective future clinical probabilities rather than current earnings.
Competition risk (biologics and immunology)HighAclaris competes against heavily funded pharmaceutical firms developing similar immunology treatments.
Business qualityMediumThe company has strong scientific platforms and experienced leadership, but lacks commercial commercialized assets.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies entirely on successfully executing complex clinical trials and securing capital.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 555.14M USD
Price to earnings Ratio -
1Y Target Price 9.82
Price to earnings Ratio -
1Y Target Price 9.82
Volume (30-day avg) 2.8M shares
Beta 0.94
52 Weeks Range 2.46 - 6.60
Updated Date 11/20/2026
52 Weeks Range 2.46 - 6.60
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.59

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 84.62%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ACRS receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ACRS has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+50.8%) is partially offset by weak cash generation (FCF margin -603.4%), negative revenue growth (-58.2%), weak profitability (net margin -829.6%).

Financial Health Rating

★★★★★
ACRS's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 42.2%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is ACRS's strongest growth driver at +50.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-58.2%, negative) and free-cash-flow growth (-133.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 87.6% and approximately 66.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.77% supports management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 8.02%
BML Capital Management LLC 6.91%
BlackRock Inc 6.33%
Deep Track Capital, LP 5.89%
Vivo Capital, LLC 4.22%

Unit Economics (Per $1K Revenue)

★★★★★
ACRS generates approximately $733 of gross profit, $-9,759 of operating income, and $-6,034 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ACRS has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
License Fees and RoyaltiesMilestone payments and royalties generated from out-licensed dermatological or drug discovery assets partnering with larger pharmaceutical firms.Revenue is currently sporadic and minor, meaning the stock trades primarily on clinical trial progress rather than product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 440.85M
Price to Sales(TTM) 86.73
Enterprise Value 440.85M
Price to Sales(TTM) 86.73
Enterprise Value to Revenue 69.12
Enterprise Value to EBITDA 0.28
Shares Outstanding 158.61M
Shares Floating 106.12M
Shares Outstanding 158.61M
Shares Floating 106.12M
Percent Insiders 6.77
Percent Institutions 87.58

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.